507TiP PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer

Autor: Hubbard, J.M., Aapro, M., Shah, S., Gabayan, A.E., Siegel, R., Pritchett, Y., Yi, J., Horton, J., Ciardiello, F.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S580-S580

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.

Autor: Ferrarotto R; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Anderson I; St Joseph Heritage Healthcare, Santa Rosa, CA, USA., Medgyasszay B; Veszprém County Lung Medicine Institute, Veszprém, Hungary., García-Campelo MR; University Hospital A Coruña, A Coruña, Spain., Edenfield W; Prisma Health Cancer Institute, Greenville, SC, USA., Feinstein TM; Piedmont Cancer Institute, Atlanta, GA, USA., Johnson JM; Thomas Jefferson University Hospital, Philadelphia, PA, USA., Kalmadi S; Ironwood Cancer & Research Center, Chandler, AZ, USA., Lammers PE; Baptist Cancer Center, Memphis, TN, USA., Sanchez-Hernandez A; Hospital Provincial de Castellon, Castelló, Spain., Pritchett Y; G1 Therapeutics, Inc., Research Triangle Park, NC, USA., Morris SR; G1 Therapeutics, Inc., Research Triangle Park, NC, USA., Malik RK; G1 Therapeutics, Inc., Research Triangle Park, NC, USA., Csőszi T; Hetenyi Geza Korhaz, Szolnok, Hungary.

Publikováno v: Cancer medicine [Cancer Med] 2021 Sep; Vol. 10 (17), pp. 5748-5756. Date of Electronic Publication: 2021 Aug 18.

MO01.40 Trilaciclib has Myelopreservation Benefits in Patients with Small Cell Lung Cancer Treated with Chemotherapy, Irrespective of Age

Autor: Beck, T., Richards, D.A., Agajanian, R., Berz, D., Chen, H., Ikpeazu, C., Tarruella, M.M., Verhoeven, D., Pritchett, Y., Malik, R.K., Antal, J.M., Hussein, M.

Publikováno v: In Journal of Thoracic Oncology January 2021 16(1) Supplement:S32-S33

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.

Autor: Daniel D; Sarah Cannon Research Institute, Tennessee Oncology-Chattanooga, Chattanooga, Tennessee, USA., Kuchava V; LTD Institute of Clinical Oncology, Tbilisi, Georgia., Bondarenko I; Dnipropetrovsk Medical Academy, Dnipro, Ukraine., Ivashchuk O; Chernivtsi Regional Clinical Oncology Centre, Chernivtsi, Ukraine., Reddy S; Northside Hospital, Inc, Atlanta, Georgia, USA., Jaal J; Department of Hematology-Oncology, University of Tartu, Tartu, Estonia., Kudaba I; Latvian Oncology Centre, Riga East University Hospital, Riga, Latvia., Hart L; Florida Cancer Specialists, Fort Myers, Florida, USA., Matitashvili A; LTD Cancer Research Centre, Tbilisi, Georgia., Pritchett Y; G1 Therapeutics, Research Triangle Park, North Carolina, USA., Morris SR; G1 Therapeutics, Research Triangle Park, North Carolina, USA., Sorrentino JA; G1 Therapeutics, Research Triangle Park, North Carolina, USA., Antal JM; G1 Therapeutics, Research Triangle Park, North Carolina, USA., Goldschmidt J; Blue Ridge Cancer Care, Blacksburg, Virginia, USA.

Publikováno v: International journal of cancer [Int J Cancer] 2021 May 15; Vol. 148 (10), pp. 2557-2570. Date of Electronic Publication: 2021 Jan 12.

Forced randomization: the what, why, and how.

Autor: Carter, Kerstine¹ (AUTHOR), Kuznetsova, Olga² (AUTHOR), Anisimov, Volodymyr³ (AUTHOR), Krisam, Johannes⁴ (AUTHOR), Scherer, Colin⁵ (AUTHOR), Ryeznik, Yevgen⁶ (AUTHOR), Sverdlov, Oleksandr⁷ (AUTHOR) alex.sverdlov@novartis.com

Publikováno v: BMC Medical Research Methodology. 10/8/2024, Vol. 24 Issue 1, p1-22. 22p.